(Burns McClellan) Amazentis, an innovative life sciences company pioneering scientific breakthroughs in nutrition to manage health conditions linked to aging, announced today Phase 1 clinical data on the safety, bioavailability, and biological activity of Urolithin A in a double-blind, randomized, placebo-controlled clinical trial in healthy elderly individuals. These data are scheduled to be presented at the International Conference on Frailty and Sarcopenia Research taking place in Barcelona, Spain, April 27-29, 2017.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2pC1eXC
No comments:
Post a Comment